Estradiol / Norethisterone / Relugolix: 4 agencies, 2021–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused estradiol / norethisterone / relugolix: all 5 decisive outcomes across 3 agencies were positive or positive with restrictions.
The record spans 4.1 years, opening at AWMSG (Wales) on 14 Jun 2021 and running to 10 Jul 2025.
SMC (Scotland) changed its position: restricted on 13 Jun 2022, recommended by 13 Jan 2025.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PBAC (Australia) and PHARMAC (New Zealand) among them — hold no record for estradiol / norethisterone / relugolix at all.
The file is active: 4 of 7 records date from 2023 or later.
4 distinct indication wordings are recorded for estradiol / norethisterone / relugolix by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess estradiol / norethisterone / relugolix, on 14 Jun 2021; AOTMIT (Poland) did not open a file until 10 Jul 2025 — a wide spread of 4.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2025 alone.
Restriction is doing real work here: 3 of 5 decisive outcomes narrowed estradiol / norethisterone / relugolix to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), SMC (Scotland) and TLV (Sweden).
3 of the 4 agencies here assessed estradiol / norethisterone / relugolix more than once, TLV (Sweden) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed estradiol / norethisterone / relugolix.
The full ledger for estradiol / norethisterone / relugolix reads 3 restricted, 2 recommended and 2 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 10 Jul 2025 | Ryeqo reimbursement recommendation | recommended conditionally | source |
| AWMSG (Wales) | 13 Feb 2025 | Treatment of symptoms of endometriosis | excluded, NICE appraised | source |
| SMC (Scotland) | 13 Jan 2025 | In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. | accepted | source |
| TLV (Sweden) | 22 Apr 2024 | Ryeqo får utökad subvention | general subsidy | source |
| SMC (Scotland) | 13 Jun 2022 | For treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. | accepted (restricted) | source |
2 further decisions for estradiol / norethisterone / relugolix, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- ethinylestradiol / levonorgestrel — same ATC class G03C — Sex hormones and modulators
- ethinylestradiol / gestodene — same ATC class G03C — Sex hormones and modulators
- estriol — same ATC class G03C — Sex hormones and modulators
- estradiol — same ATC class G03C — Sex hormones and modulators
- inclisiran — also decided by AOTMIT in 2025Q3
- lisocabtagene maraleucel — also decided by AOTMIT in 2025Q3
Coverage: 7 decisions for estradiol / norethisterone / relugolix from 4 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class G03C — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.